Evidence map›Paper›PMID 22125661›Full record

ArticleWorld journal of hepatology2011

Hepatitis C virus-related B cell subtypes in non Hodgkin's lymphoma.

Adriano M Pellicelli, Massimo Marignani, Valerio Zoli, Mario Romano, Aldo Morrone, Lorenzo Nosotti, Giuseppe Barbaro, Antonio Picardi, Umberto Vespasiani Gentilucci, Daniele Remotti and 8 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of hepatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Adriano M PellicelliAdriano M Pellicelli, Cecilia D'Ambrosio, Roberto Villani, Arnaldo Andreoli, Liver Unit, Azienda Ospedaliera San Camillo Forlanini, Circonvallazione Gianicolense 87, 00149 Rome, Italy.
Massimo Marignani
Valerio Zoli
Mario Romano
Aldo Morrone
Lorenzo Nosotti
Giuseppe Barbaro
Antonio Picardi
Umberto Vespasiani Gentilucci
Daniele Remotti
Cecilia D'Ambrosio
Caterina Furlan
Fabrizio Mecenate
Ettore Mazzoni
Ignazio Majolino
Roberto Villani
Arnaldo Andreoli
Giorgio Barbarini
Azienda Ospedaliera San Camillo-Forlanini · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo evaluate if indolent B cell-non Hodgkin's lymphoma (B-NHL) and diffuse large B-cell lymphoma (DLBCL) in hepatitis C virus (HCV) positive patients could have different biological and clinical characteristics requiring different management strategies.

methodsA group of 24 HCV related B-NHL patients (11 indolent, 13 DLBCL) in whom the biological and clinical characteristics were described and confronted. Patients with DLBCL were managed with the standard of care of treatment. Patients with indolent HCV-related B-NHL were managed with antiviral treatment pegylated interferon plus ribavirin and their course observed. The outcomes of the different approaches were compared.

resultsPatients with DLBCL had a shorter duration of HCV infection and a higher prevalence of HCV genotype 1 compared to patients with indolent B-NHL in which HCV genotype 2 was the more frequent genotype. Five of the 9 patients with indolent HCV-related B-NHL treated with only antiviral therapy, achieved a complete response of their onco-haematological disease (55%). Seven of the 13 DLBCL patients treated with immunochemotheraphy obtained a complete response (54%).

conclusionHCV genotypes and duration of HCV infection differed between B-NHL subtypes. Indolent lymphomas can be managed with antiviral treatment, while DLBCL is not affected by the HCV infection.

Indexed as

Diffuse large B cell lymphomaHepatitis C virus infectionIndolent lymphomaLymphomagenesisPegylated interferon

Identifiers

PMID22125661
PMCPMC3225032
OpenAlexW2127081102

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.